These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 31862616)

  • 41. Developments on treatment of Chagas disease - from discovery to current times.
    Custodio Leite TO
    Eur Rev Med Pharmacol Sci; 2019 Mar; 23(6):2576-2586. PubMed ID: 30964186
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Repositioned Drugs for Chagas Disease Unveiled via Structure-Based Drug Repositioning.
    Adasme MF; Bolz SN; Adelmann L; Salentin S; Haupt VJ; Moreno-Rodríguez A; Nogueda-Torres B; Castillo-Campos V; Yepez-Mulia L; De Fuentes-Vicente JA; Rivera G; Schroeder M
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233837
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of the anti-Trypanosoma cruzi activity in vitro and in vivo of silibinin and silibinin in association to benznidazole.
    Torchelsen FKVDS; Silva TM; Milagre MM; Silva RR; Reis LES; Branquinho RT; Silva GN; de Lana M
    Parasitol Res; 2021 Apr; 120(4):1511-1517. PubMed ID: 33236174
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Médecins Sans Frontières.
    Yun O; Lima MA; Ellman T; Chambi W; Castillo S; Flevaud L; Roddy P; Parreño F; Albajar Viñas P; Palma PP
    PLoS Negl Trop Dis; 2009 Jul; 3(7):e488. PubMed ID: 19582142
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease.
    Rial MS; Scalise ML; Arrúa EC; Esteva MI; Salomon CJ; Fichera LE
    PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006119. PubMed ID: 29267280
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical and pharmacological profile of benznidazole for treatment of Chagas disease.
    Kratz JM; Garcia Bournissen F; Forsyth CJ; Sosa-Estani S
    Expert Rev Clin Pharmacol; 2018 Oct; 11(10):943-957. PubMed ID: 30111183
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nitroheterocyclic drugs cure experimental Trypanosoma cruzi infections more effectively in the chronic stage than in the acute stage.
    Francisco AF; Jayawardhana S; Lewis MD; White KL; Shackleford DM; Chen G; Saunders J; Osuna-Cabello M; Read KD; Charman SA; Chatelain E; Kelly JM
    Sci Rep; 2016 Oct; 6():35351. PubMed ID: 27748443
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Benznidazole shortage makes chagas disease a neglected tropical disease in developed countries: data from Spain.
    Navarro M; Norman FF; Pérez-Molina JA; López-Vélez R
    Am J Trop Med Hyg; 2012 Sep; 87(3):489-90. PubMed ID: 22826485
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Detection and treatment of Trypanosoma cruzi: a patent review (2011-2015).
    Rodriguez JB; Falcone BN; Szajnman SH
    Expert Opin Ther Pat; 2016 Sep; 26(9):993-1015. PubMed ID: 27376456
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Why hasn't there been more progress in new Chagas disease drug discovery?
    Vermelho AB; Rodrigues GC; Supuran CT
    Expert Opin Drug Discov; 2020 Feb; 15(2):145-158. PubMed ID: 31670987
    [No Abstract]   [Full Text] [Related]  

  • 51. Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi.
    Brand S; Ko EJ; Viayna E; Thompson S; Spinks D; Thomas M; Sandberg L; Francisco AF; Jayawardhana S; Smith VC; Jansen C; De Rycker M; Thomas J; MacLean L; Osuna-Cabello M; Riley J; Scullion P; Stojanovski L; Simeons FRC; Epemolu O; Shishikura Y; Crouch SD; Bakshi TS; Nixon CJ; Reid IH; Hill AP; Underwood TZ; Hindley SJ; Robinson SA; Kelly JM; Fiandor JM; Wyatt PG; Marco M; Miles TJ; Read KD; Gilbert IH
    J Med Chem; 2017 Sep; 60(17):7284-7299. PubMed ID: 28844141
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rate-of-Kill (RoK) assays to triage large compound sets for Chagas disease drug discovery: Application to GSK Chagas Box.
    Cantizani J; Gamallo P; Cotillo I; Alvarez-Velilla R; Martin J
    PLoS Negl Trop Dis; 2021 Jul; 15(7):e0009602. PubMed ID: 34270544
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chagas disease: Present status of pathogenic mechanisms and chemotherapy.
    Maya JD; Orellana M; Ferreira J; Kemmerling U; López-Muñoz R; Morello A
    Biol Res; 2010; 43(3):323-31. PubMed ID: 21249304
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Nifurtimox, a bright future for treatment of Chagas disease].
    Wolf A; Boulliat C; Coillot C; Rouault M; Gaillard K; Beranger C; Oliver M
    Med Trop (Mars); 2011 Apr; 71(2):131-3. PubMed ID: 21695868
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel Therapeutic Options for Chagas Disease Based on Bioactive Compounds from Algae, Bacteria and Fungi Species.
    da Silva MV; Gondim BLC; de Carvalho-Costa TM; Mendes MT; Lemes MR; Barbosa RM; Cardoso TN; Nascimento NS; Barros DB; da Silva MV; Machado JR; Castellano LRC
    Curr Med Chem; 2021; 28(36):7513-7528. PubMed ID: 34365936
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Natural and synthetic naphthoquinones active against Trypanosoma cruzi: an initial step towards new drugs for Chagas disease.
    Salas CO; Faúndez M; Morello A; Maya JD; Tapia RA
    Curr Med Chem; 2011; 18(1):144-61. PubMed ID: 21110810
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Trypanothione Reductase and Superoxide Dismutase as Current Drug Targets for Trypanosoma cruzi: An Overview of Compounds with Activity against Chagas Disease.
    Beltran-Hortelano I; Perez-Silanes S; Galiano S
    Curr Med Chem; 2017 May; 24(11):1066-1138. PubMed ID: 28025938
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chagas Disease: A Solvable Problem, Ignored.
    Tarleton RL
    Trends Mol Med; 2016 Oct; 22(10):835-838. PubMed ID: 27523778
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of novel benznidazole solutions during the experimental infection with Trypanosoma cruzi.
    Manarin R; Lamas MC; Bottasso E; Serra E; Revelli S; Salomón CJ
    Parasitol Int; 2013 Feb; 62(1):79-81. PubMed ID: 22975280
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease.
    Filardi LS; Brener Z
    Trans R Soc Trop Med Hyg; 1987; 81(5):755-9. PubMed ID: 3130683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.